Neuromyelitis Optica Spectrum Disorder Medication, Ultomiris by AstraZeneca, Set for EU Approval

AstraZeneca’s new medication for people with neuromyelitis optica spectrum disorder is set to go to market in the European Union, according to the company.

Following the outcomes of a Phase 3 study, the pharmaceutical titan revealed that their Ultomiris drug generated a good impression from the Committee for Medicinal Products for Human Use, a branch of the European Medicines Agency.

Ultomiris, which is intended for people who are suffering with neuromyelitis optica spectrum disorder and are anti-aquaporin-4 antibody positive, has reportedly fulfilled its primary goal.

If approved, this will be a pioneering therapy option on the market, the sole option available in the EU that contains a lasting complement inhibitor.

AstraZeneca’s Ultomiris administrative filings are also being examined by several health officials, such as those in the United States. and Japan.

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.